Search results
Results From The WOW.Com Content Network
The center was formed in 1974 by the merger of the American Oncologic Hospital, which was founded in 1904 as the first cancer hospital in the United States, [2] and the Institute for Cancer Research, founded in 1927.
In 2010, McKesson acquired the oncology and physician services company US Oncology, Inc. for $2.16 billion, which was integrated into the McKesson Specialty Health business. [21] In April 2012, McKesson agreed to pay the United States $190M to settle allegations that it had inflated prices and overbilled Medicaid. [22]
Cancer Treatment Centers of America (CTCA), headquartered in Boca Raton, Florida, was a national, for-profit network of five comprehensive cancer care and research centers and three outpatient care centers that served cancer patients throughout the United States.
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Dana–Farber Cancer Institute (DFCI) is a comprehensive cancer treatment and research center in Boston, Massachusetts.Dana-Farber is the founding member of the Dana-Farber/Harvard Cancer Center, Harvard's Comprehensive Cancer Center designated by the National Cancer Institute, and one of the 15 clinical affiliates and research institutes of Harvard Medical School.
Varian Medical Systems is an American radiation oncology treatments and software maker based in Palo Alto, California.Their medical devices include linear accelerators (LINACs) and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy.
He became CEO of US Oncology in 2008, and chairman a year later. [14] In 2011, Broussard became president of Humana and in 2013, was promoted to CEO, succeeding Michael B. McCallister. Under Broussard's tenure, Humana's revenue grew to $92.9 billion in 2022 from $39.1 billion in 2012 and its net income doubled to $2.8 billion.
McKesson would acquire about a 70% stake in the unit, which would be part of its U.S. pharmaceutical segment. Upon the close of the transaction, Florida Cancer Specialists — which operates in ...